ANEW PHARMA

Anew Medical is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases and age-related disorders by targeting the Klotho protein. The company's primary focus is on restoring levels of Klotho, a naturally occurring neuroprotective and anti-aging protein that declines with age and is linked to conditions such as Alzheimer's and ALS. Anew Medical utilizes a dual approach, developing high-value gene therapies and recombinant proteins alongside a portfolio of advanced nutraceuticals and medical devices. Recently listed on the Nasdaq, the company maintains significant research operations in Barcelona, Spain, and is advancing its lead gene therapy candidate, ANW-101, toward clinical trials.